Trade

Watchlist

Portfolio

Message

Set Alert

BSE LIVE NSE LIVE 26 Aug, 2025 12:21 Volume Todays L/H More ×

Gland Pharma Ltd. on Monday reported a net profit of Rs. 183.7 core, a 12% year-on-year rise in net profit for the second quarter of FY26, driven by strong performance in the US and European markets, margin expansion, and a growing pipeline of complex injectables.

Consolidated revenue rose 6% to Rs 1487 crore, while EBITDA grew 6% to Rs 313.9 crore. Adjusted EBITDA margins improved 150 basis points to 23%.

The company’s base business — excluding its European subsidiary Cenexi — posted a 7% increase in profit after tax, with EBITDA margins holding steady at 35%.

“Gland Pharma delivered a strong first half of FY26, with revenue growth of 7% and PAT up by 30

See Full Page